Preclinical Research is a facility within the Scientific Directorate where translational preclinical research activities can be conducted. The facility was authorized by the Ministry of Health with decree no. 10/2017-UT dated 09/05/2017. In compliance with Articles 25 and 26 of Legislative Decree 26/2014, RP has established the OPBA, a body for the oversight and support of scientific activities adhering to the 3Rs principle and current legislation (Legislative Decree 26/2014 and Directive 2010/63/EU).
The RP Service Charter includes:
-
Coordination, development, and alignment of preclinical research activities of the Foundation’s Research Groups.
-
Maintenance, management, and monitoring of animal welfare.
-
Supervision and oversight regarding compliance by all Foundation Research Groups with legal requirements for protection and welfare.
-
Technical-scientific support for drafting research protocols; review of protocols prior to submission to OPBA.
-
Assistance in performing experimental procedures: 1) surgical and anesthesiological procedures; 2) pharmacological treatments; 3) in vivo imaging; 4) processing of biological samples for biomolecular analyses.
-
Theoretical and practical training for researchers on various technical-experimental activities according to Ministerial Decree of August 5, 2021, and Director’s Decree of March 18, 2022.
-
Management of administrative and operational activities related to OPBA functioning. Care and preservation of documentation relevant to research projects (Ministerial Authorization, Integrations, and Retrospective Evaluations).
-
Management of documentation regarding facility operation and use of structure and equipment, to be presented during planned and unplanned inspections by the Ministry of Health and Competent Authority (art. 30, Legislative Decree 26/2014).
-
Annual reporting to the European Union of experimental procedures performed.